Clinical trials: Atopic Eczema
Atopic Dermatitis
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device.
- Trial name
- Detect-AD (NCT07645820)
- Testing
- Nevisense electrical impedance spectroscopy
- Where
- 13 sites in United States
- Volunteers
- 450 people
- Sponsor
- Castle Biosciences Incorporated
Dermatitis, Atopic
A Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis
This is a randomized, double-blind, placebo-controlled, parallel group study to confirm the efficacy and safety of MG-K10 monotherapy in adolescents with moderate-to-severe atopic dermatitis (AD)
- Trial name
- NCT07540442
- Testing
- MG-K10 Injection (Humanized Monoclonal Antibody)
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Atopic Dermatitis
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
The objectives of this prospective non-interventional study are to characterize the existing unmet needs across the spectrum of atopic dermatitis (AD), enhance the understanding of the patient journey, and evaluate the safety and…
- Trial name
- ARMADA-AD (NCT07290803)
- Where
- 82 sites in United States, Canada and 7 more
- Volunteers
- 1,000 people
- Sponsor
- Sanofi
Dermatitis Atopic
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 years and older diagnosed with moderate-to-severe atopic dermatitis (AD).
- Trial name
- ESTUARY (NCT06407934)
- Testing
- Amlitelimab
- Where
- 324 sites in United States, Argentina and 25 more
- Volunteers
- 1,541 people
- Sponsor
- Sanofi
Atopic Eczema
A Study to Evaluate the Emollient Performance of Doublebase Once in the Treatment of Atopic Eczema
A 4 week, open label, multi-centre (GP setting), post market clinical follow-up study with Doublebase Once in patients of any age and any severity of atopic eczema.
- Trial name
- NCT06453512
- Testing
- Doublebase Once
- Where
- United Kingdom
- Volunteers
- 65 people
- Sponsor
- Dermal Laboratories Ltd
Atopic Dermatitis
A Phase I Study to Assess the Safety and Tolerability of Topical CRx-197 Formulations in Healthy Volunteers
This will be a phase I, single center, randomized, vehicle-controlled, blinded study comparing two dosage strengths of CRx-197 cream, nortriptyline, an active comparator (0.1% mometasone) and placebo (the active ingredient free…
- Trial name
- NCT00721331
- Testing
- nortriptyline HCl + loratadine, nortriptyline HCl, mometasone furoate
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Zalicus
Atopic Dermatitis
A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to describe the efficacy and safety of LY3454738 in adult participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT05911841
- Testing
- LY3454738
- Where
- 66 sites in United States, Canada and 7 more
- Volunteers
- 234 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Safety and Bioequivalence of Pimecrolimus Cream 1% and Elidel R in Treatment of Mild to Moderate Atopic Dermatitis
A phase 3, double-blind, randomized, parallel-group, placebo-controlled, multicenter study to evaluate the safety and bioequivalence of Par Pharmaceutical Inc.'s Pimecrolimus Cream, 1% and Reference Listed Elidel® (Pimecrolimus…
- Trial name
- NCT03297502
- Testing
- pimecrolimus cream 1%, Elidel (pimecrolimus) cream 1%
- Volunteers
- 582 people
- Sponsor
- Par Pharmaceutical, Inc.
Dermatitis, Atopic
A Single Dose Phase I Exploratory Study in Healthy Volunteers With GSK2894512 Cream
This will be an open-label, non-randomized, single-center study to assess the residency of GSK2894512 in the skin of healthy adult male volunteers with normal barrier function.
- Trial name
- NCT02411162
- Testing
- Combination therapy GSK2894512 Cream A + GSK2894512 Cream B, Combination therapy Vehicle Cream A + Vehicle Cream B
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Stiefel, a GSK Company
Atopic Dermatitis (AD)
To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD
This is a multinational (China and Korea), multicenter, randomized, double-blind, vehicle-controlled, parallel-group, comparison trial to demonstrate the superiority of 1% OPA-15406 ointment to the vehicle in adult AD subjects.
- Trial name
- NCT05667623
- Testing
- 1% OPA-15406 Ointment, 0% OPA-15406 Vehicle
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Otsuka Beijing Research Institute
Mild to Moderate Atopic Dermatitis
Efficacy and Safety of an Ectoine-containing Cream in the Treatment of Mild to Moderate Atopic Dermatitis
This study evaluates the efficacy of the topical used ectoine-formulation EHK02-01 compared to Atopiclair. Patients are examined at visit 2 (baseline visit).
- Trial name
- NCT01079897
- Testing
- Atopiclair, EHK02-01
- Where
- 4 sites in Germany
- Volunteers
- 64 people
- Sponsor
- Bitop AG
Atopic Dermatitis, Healthy
Assessment of Clinical, Biological and Biometrological Parameters in Adults Subjects With Atopic Dermatitis
In most recent years, the gut microbiome has been highlighted as a key player in the control of organs distant from the gut. Indeed, studies have raised evidence that gut microbiota exerts a control on various diseases including…
- Trial name
- NCT07017348
- Testing
- Clinical assessments, Biometrological measurements, Biological sampling
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Dermo Cosmetique
Atopic Dermatitis
Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement
This is a randomized, double blind, vehicle controlled Phase 2 study with a 4-week open label extension in adolescent and adult participants with atopic dermatitis and head and/or neck involvement.
- Trial name
- NCT05127421
- Testing
- Ruxolitinib cream, Vehicle
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis
A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable
The purpose of this study is to determine the efficacy and safety of baricitinib in combination with topical corticosteroids in participants with moderate to severe atopic dermatitis who have experienced failure to cyclosporine…
- Trial name
- BREEZE-AD4 (NCT03428100)
- Testing
- Baricitinib, Topical corticosteroid
- Where
- 103 sites in Austria, Belgium and 12 more
- Volunteers
- 463 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis
The purpose of this study is to assess the efficacy and safety of twice daily ruxolitinib cream in adolescents and adults with Atopic Dermatitis (AD).
- Trial name
- NCT03745638
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 79 sites in United States, Canada and 5 more
- Volunteers
- 631 people
- Sponsor
- Incyte Corporation
Eczema, Atopic Dermatitis
A Study to Evaluate CLn® BodyWash As Added Therapy in Eczema Patients
The purpose of this study is to determine if CLn BodyWash, a novel new gel cleanser formulated with surfactants and preserved with sodium hypochlorite, is effective at decreasing severity, body surface area and itching for…
- Trial name
- CLeaN (NCT01714245)
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- TopMD Skin Care, Inc.
Atopic Dermatitis (AD), Eczema
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
This is a first-in-human, Phase 1, double-blind, randomized, placebo-controlled, dose-escalation study evaluating ARQ-234. The study is designed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD)…
- Trial name
- NCT07453602
- Testing
- ARQ-234
- Where
- 7 sites in United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Arcutis Biotherapeutics, Inc.
Atopic Dermatitis
10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus
This study will examine the risk of systemic malignancies in pediatric patients with atopic dermatitis exposed to Elidel 1% cream.
- Trial name
- PEER (NCT00568997)
- Testing
- Pimecrolimus
- Where
- United States
- Volunteers
- 8,000 people
- Sponsor
- Bausch Health Americas, Inc.
Dermatitis, Atopic
Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis
The purpose of this study is to investigate the safety, tolerability, and systemic exposure of AN2728 Topical Ointment, 2%, in subjects with atopic dermatitis.
- Trial name
- NCT01652885
- Testing
- AN2728 Topical Ointment, 2%
- Where
- 6 sites in United States
- Volunteers
- 23 people
- Sponsor
- Pfizer
Atopic Dermatitis (AD)
A Phase III Study of GS101 Injection to Dupixent®
This is a a multicenter, randomized, double-blinded, parallel, positive-controlled, Phase III comparative study to evaluate GS101 Injection versus Dupixent® in participants with moderate-to-severe atopic dermatitis.
- Trial name
- NCT07386743
- Testing
- GS101 injection, DUPIXENT®
- Where
- China
- Volunteers
- 572 people
- Sponsor
- Jiangsu Genscend Biopharmaceutical Co., Ltd